Pouleur H, Etienne J, Van Mechelen H, Van Eyll C, Charlier A A, Brasseur L A, Rousseau M F
Postgrad Med J. 1984;60 Suppl 4:23-8.
To assess the added effects of nicardipine and beta-blockers on the left ventricular (LV) function, 2.5 mg of i.v. nicardipine was given to 9 patients with coronary artery disease, pretreated with propranolol (0.1 mg/kg, i.v.). The changes in LV function observed after nicardipine were compared with those induced by nifedipine (20-30 mg sublingually), in 8 comparable patients also pretreated with propranolol. Nicardipine normalized the cardiac output and the rate of LV relaxation, both depressed by propranolol, without changes in LV filling pressure. After nicardipine, end-systolic volume (52 to 42 ml/m2; P less than 0.01) and ejection fraction (59 +/- 8 to 66 +/- 9%; P less than 0.01) improved; the mean systolic and diastolic wall stresses decreased respectively by 19% (P less than 0.01) and 21% (P less than 0.01) whereas the maximal LV pressure/volume ratio (Emax), an index of LV inotropic state, was unchanged (+4%; NS). Further, although nicardipine and nifedipine produced identical changes in LV systolic pressure (-25 vs -26 mmHg; NS nicardipine vs nifedipine) and in heart rate, the changes in end-systolic volume (-9 +/- 4 vs -3 +/- 9 ml/m2; P less than 0.005), in Emax (+0.14 +/- 0.31 vs -0.20 +/- 0.22 mmHg/ml/m2; P less than 0.025) and in ejection fraction (+7 +/- 4 vs +2 +/- 4%; P less than 0.025) were significantly greater after nicardipine than after nifedipine. In conclusion, nicardipine administered after propranolol improves LV pump function and has no negative inotropic effects as indicated by the lack of dP/dt Max and Emax changes. These additive effects of nicardipine after propranolol were greater than those of nifedipine administered at an equipotent vasodilator dosage.
为评估尼卡地平和β受体阻滞剂对左心室(LV)功能的附加作用,对9例冠心病患者静脉注射2.5 mg尼卡地平,这些患者已预先静脉注射普萘洛尔(0.1 mg/kg)。将尼卡地平给药后观察到的左心室功能变化与8例同样预先使用普萘洛尔的类似患者舌下含服硝苯地平(20 - 30 mg)后诱导的变化进行比较。尼卡地平使心输出量和左心室舒张速率恢复正常,这两者均因普萘洛尔而降低,且左心室充盈压无变化。使用尼卡地平后,收缩末期容积(从52降至42 ml/m²;P < 0.01)和射血分数(从59 ± 8%提高到66 ± 9%;P < 0.01)得到改善;平均收缩期和舒张期壁应力分别降低19%(P < 0.01)和21%(P < 0.01),而左心室收缩性状态指标最大左心室压力/容积比(Emax)未改变(+4%;无显著性差异)。此外,尽管尼卡地平和硝苯地平在左心室收缩压(-25 mmHg对-26 mmHg;尼卡地平与硝苯地平无显著性差异)和心率方面产生相同变化,但尼卡地平给药后收缩末期容积的变化(-9 ± 4 ml/m²对-3 ± 9 ml/m²;P < 0.005)、Emax的变化(+0.14 ± 0.31 mmHg/ml/m²对-0.20 ± 0.22 mmHg/ml/m²;P < 0.025)和射血分数的变化(+7 ± 4%对+2 ± 4%;P < 0.025)均显著大于硝苯地平给药后。总之,普萘洛尔给药后给予尼卡地平可改善左心室泵功能,且如未出现dP/dt Max和Emax变化所示,无负性肌力作用。普萘洛尔给药后尼卡地平的这些附加作用大于等剂量血管扩张剂硝苯地平的作用。